<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101061</url>
  </required_header>
  <id_info>
    <org_study_id>20090378</org_study_id>
    <nct_id>NCT01101061</nct_id>
  </id_info>
  <brief_title>A Single-dose Study Evaluating AMG 785 in Healthy Postmenopausal Japanese Women</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Postmenopausal Japanese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and potential immune response
      of AMG 785 following single subcutaneous (SC, injection under the skin) dose administration
      in healthy postmenopausal Japanese women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number (percent) of subjects experiencing clinically significant changes in vital signs, physical exams, laboratory safety tests, and ECGs</measure>
    <time_frame>A maximum of 85 days following investigational product administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number (percent) of subjects who develop anti-AMG 785 antibodies</measure>
    <time_frame>A maximum of 85 days following investigational product administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number (percent) of subjects reporting treatment-emergent adverse events</measure>
    <time_frame>A maximum of 85 days following investigational product administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) and pharmacodynamic (PD) parameters [procollagen type 1 N-terminal propeptide (P1NP), serum C-telopeptide (sCTX) and sclerostin] following single subcutaneous (SC) dose administration in Japanese and non-Japanese women</measure>
    <time_frame>A maximum of 85 days following investigational product administration.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>AMG 785</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six (6) Japanese women in cohorts 1, 2, and 4 will receive a single weight-based dose of AMG 785. Four (4) non-Japanese women in cohort 3 will receive a single weight-based dose of AMG 785.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two (2) women in each of cohorts 1, 2, 3, and 4 will receive a single dose of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 785</intervention_name>
    <description>Subjects will be randomized to receive one of 3 dose levels of AMG 785 or equivalent volume of placebo administered as a single weight-based dose. Postmenopausal Japanese women will receive AMG 785 at a dose level of 1 mg/kg, 3 mg/kg, or 5 mg/kg. Postmenopausal non-Japanese women will receive AMG 785 at a dose level of 3 mg/kg.</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Subjects will be randomized to receive one of 3 dose levels of AMG 785 or equivalent volume of placebo administered as a single weight-based dose. Postmenopausal Japanese women will receive AMG 785 at a dose level of 1 mg/kg, 3 mg/kg, or 5 mg/kg. Postmenopausal non-Japanese women will receive AMG 785 at a dose level of 3 mg/kg.</description>
    <arm_group_label>AMG 785</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese subjects must be first (4 grandparents, biologic parents and subject born in
             Japan), second (4 grandparents and biological parents born in Japan) or third (4
             grandparents born in Japan) generation Japanese

          -  Body mass index ≤ 25 kg/m2, inclusive at screening

          -  Postmenopausal females defined as 12 continuous months of spontaneous amenorrhea
             confirmed by a serum follicle-stimulating hormone (FSH) result &gt; 40mIU/mL, or 6 weeks
             postsurgical bilateral oophorectomy (with or without hysterectomy) as documented in
             medical history (verified with an operative note, if available)

        Exclusion Criteria:

          -  Osteoporosis, as defined by bone mineral density (BMD) T-scores of the lumbar spine
             (L1-L4) or total evaluable vertebrae (if fewer than L1-L4); or femoral neck ≤ -2.5

          -  History of vertebral fracture or fragility fracture of the wrist, humerus, hip or
             pelvis;

          -  Diagnosed with any condition that will affect bone metabolism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>March 31, 2011</last_update_submitted>
  <last_update_submitted_qc>March 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

